Nano-LYTAC Nanotherapeutic platform for lysosomal targeted technology
- Coordinator
- Univerzita Palackeho V Olomouci, Czechia
- Runs
- 12 January 2026 to 11 January 2028
- Status
- Running
- EU funding
- €208k
- Total cost
- —
- Partners
- 2 organisations in 1 countries
- Type
- Marie Skłodowska-Curie Action
- Grant agreement
- 101211450
What the project is doing
In the project's own words, from its summary on CORDIS.
Cancer remains a tough challenge, largely because 80% of cancer-driving proteins are considered “undruggable” meaning impossible to target with conventional therapies. Nano-LYTAC project brings together experts in nanomedicine, pharmaceutical technology, and nanotoxicology to answer the burning question: Does complete cancer eradication still remain as an elusive dream? By combining 2 cutting-edge technologies: “Smart Nanotechnology” and “Targeted Protein Degraders (TPDs)”, this project fulfills the goals of Europe’s Beating Cancer Plan by tackling these undruggable proteins.
TPDs were created using Nobel Prize-winning bioorthogonal chemistry. Among these, LYTACs (Lysosomal Targeting Chimeras), with their ability to transport intracellular/extracellular cancer-driving protein for selective degradation in the lysosomes, abrogate the cancer pathology. However, despite their promise, LYTACs haven’t made it to clinical use yet, owing to challenges like limited molecule diversity, poor tumor penetration, low bioavailability, and metabolic instability.
To transform LYTACs into clinically viable cancer therapies, and to overcome the aforementioned drawbacks, this project will use novel nanotechnological approach to enable enhanced tumor penetration, selectivity, protection, and controlled released of the LYTACs in tumor microenvironment. Moreover, for the first time, I will design new LYTAC molecules specifically targeting folate receptors that are overexpressed on many types of cancers (e.g.: breast cancers, lung cancer, ovarian cancers).
At CATRIN, under the guidance of Prof. Kateřina Poláková, an expert in nanomedicine and their subcellular trafficking, and nanotoxicology, I will develop ""Smart Nano-LYTACs"" with the preclinical proof of their potential. This multidisciplinary project will also enhance my skills in nanotherapeutics and cancer biology, helping me to work towards my long-term goal of establishing my own research group focused on advanced cancer therapies.""
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Univerzita Palackeho V Olomouci | Olomouc | Czechia | Coordinator |
| Univerzita Karlova | Praha 1 | Czechia | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI